Navigation Links
Heptares Secures GBP21 Million in Series A Fund Raising to Accelerate Development of Pipeline of Small Molecules Against High-Value GPCR Drug Targets
Date:2/24/2009

LONDON, February 24 /PRNewswire/ --

- Syndicate Comprises Leading Sector Investors Clarus Ventures, MVM Life Science Partners and Novartis Option Fund

Heptares Therapeutics Ltd, the drug discovery company focused on drugs targeting G-protein-coupled receptors (GPCRs), announces today it has raised GBP21 million (US$30 million) of equity finance in a successful Series A private round from three blue-chip international venture capital firms. Clarus Ventures led the syndicate, which includes the founding investor, MVM Life Science Partners, and the Novartis Option Fund. All three investors contributed equally.

Michael Steinmetz for Clarus Ventures and Anja Koenig for the Novartis Option Fund have joined the Heptares Board of Directors as non-executive directors.

Over the next three years, Heptares intends to use the new funds to develop its own pipeline of small-molecule drug candidates using its proprietary StaR(TM) technology platform. These novel drug candidates will be developed against currently intractable GPCRs that are highly validated targets for the treatment of disease. Further progress in the application of StaR technology over this period is also expected to yield commercial partnering opportunities outside Heptares' core focus, for example, improved therapeutic antibodies against GPCRs.

GPCRs play a crucial role in many diseases and are the site of action of 25-30% of current drugs; as such they represent a major area of interest for pharmaceutical companies. However, these membrane proteins are notoriously difficult to isolate from cells in an intact and active form and this has severely restricted efforts to study GPCRs using modern drug discovery techniques.

Heptares' StaR (Stabilised Receptor) technology platform enables the Company to overcome this technology hurdle by engineering and purifying GPCRs in stable and functional conformat
'/>"/>

SOURCE Heptares Therapeutics Ltd
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Sopherion Therapeutics Secures $55 Million in Series C Funding
2. Northwest Biotherapeutics Secures $700,000 Equity Financing
3. Intelligroup Secures Multi-Million Dollar COSMOS Implementation with Almac Clinical Services
4. TaiGen Biotechnology Secures 37 Million USD in Series C Round Financing
5. Pharmacyclics Secures $5.0 Million in Debt Financing
6. EcoSphere(R) Biolatex(TM) Secures Funding from Granholm and Invest Michigan!
7. Interface Biologics secures $5mm financing and appoints Thomas P. Reeves President and Chief Executive Officer
8. Queens secures £25M for UKs cyber safety
9. Queens secures £25m for UKs cyber-safety
10. Northwest Secures US$1.65 Million Debt Financing
11. NeoStem Secures $250,000 in an Above Market Financing and Expands Its Relationship With New England Cryogenic Center, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/18/2014)... Diego, CA (PRWEB) November 17, 2014 Athena ... of Salk , Dr. Beverly Emerson, a professor in the ... of genes. Her most recent discovery points to an “off ... Dr. Emerson’s career and how her local research is making ... will present her findings and then join host Cheryl K. ...
(Date:11/18/2014)... Georgia (PRWEB) November 18, 2014 ... (Melbourne, Australia) recently formed a partnership with researchers ... Swinburne University of Technology, and the USDA’s Forest ... components reinforced with nanocellulose. Nanocellulose is a rapidly ... goal of the project is to replace heavy ...
(Date:11/18/2014)... 18, 2014 2014 Deep ... is professional and in-depth report on Polytetrahydrofuran ... information, including its definition, characterization, application, and ... This exploration covers the worldwide business investigation, ... examination covering macroeconomic environment & financial circumstance ...
(Date:11/18/2014)... Nev. , Nov. 18, 2014 PDL ... announced that in connection with the acquisition of Durata ... million in connection with the termination of PDL,s credit ... principal amount outstanding of $40 million, accrued interest, and ... PDL entered into a structured financing transaction with Durata ...
Breaking Biology Technology:American Process Inc. Announces Partnership to Develop Ultra-Strong, Lightweight Automotive Components Using Nanotechnology from Nature 2American Process Inc. Announces Partnership to Develop Ultra-Strong, Lightweight Automotive Components Using Nanotechnology from Nature 3PTMEG Market: 2019 Global Polytetrahydrofuran Industry Development Trends & Analysis Now at DeepResearchReports.com 2PTMEG Market: 2019 Global Polytetrahydrofuran Industry Development Trends & Analysis Now at DeepResearchReports.com 3PDL BioPharma Announces Successful Conclusion of Debt Financing Agreement with Durata Therapeutics 2
... Genesis Biopharma, Inc. (OTC Bulletin Board: ... today announced that President and CEO Robert Brooke will ... Forum Biotech, Healthcare & Pharma Virtual Conference.  The webcast ... p.m. Eastern time (10:00 a.m. Pacific time) by visiting ...
... University have discovered new properties in a material that ... for pollution-free electricity production. The discovery, posted online ... the journal Nature Materials , reveals that energy-carrying ... the order of a thousand times farther in organic ...
... 8 IntegenX, Inc. (IXI) today announced that ... the Defense Threat Reduction Agency (DTRA) of the ... Integrated Sample-to-Sequence (ISS) system for rapid detection and ... relevant bacteria and viruses, and emerging pathogens. IntegenX ...
Cached Biology Technology:Genesis Biopharma to Present at the Informed Investors Forum Biotech, Healthcare & Pharma Virtual Conference on October 13 2Rutgers discovery paves way for development of efficient, inexpensive plastic solar cells 2IntegenX Awarded DTRA Contract to Develop Pathogen Detection and Identification Platform 2
(Date:11/3/2014)... DUBLIN , Nov. 3, 2014 Research ... report "Cell Therapy - Technologies, Markets and Companies" ... evaluates cell therapy technologies and methods, which have already started ... Hematopoietic stem cell transplantation is replacing the old fashioned bone ... described. Cell therapy is bound to become a part of ...
(Date:11/3/2014)... weight and preterm birth are linked to increased risk ... in the American College of Rheumatology (ACR) journal, ... weight and pre-term babies were not at greater risk ... , According to the ACR, 27 million Americans over ... Symptoms of OA range from mild to severe and ...
(Date:11/2/2014)... fascinating to put a flashlight up to our palms ... University in St. Louis engineers are using a similar ... improve imaging of cancerous tissues and to develop potential ... Beare Distinguished Professor of Biomedical Engineering at the School ... time-reversal technology that allows researchers to better focus light ...
Breaking Biology News(10 mins):Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 2Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 3Preterm, low birth-weight babies may need new hips in adulthood 2Improving imaging of cancerous tissues by reversing time 2
... Boston Universitys College of Engineering may have discovered ... defeating so-called superbugs, bacteria that have developed resistance ... previously unknown chain of events occurring in bacteria ... research. Currently, three classes of bactericidal ...
... Efforts to make open-heart surgery a minimally invasive ... Institutes of Health Bioengineering Research Partnership award. Professor ... cardiac surgeon Pedro del Nido, M.D., at Childrens ... Inc. (Van Nuys, CA) will collaborate to develop ...
... says, is an essential peptide factor for the growth ... that this growth factor is important for the nervous ... in the October 7 issue of the World Journal ... about this growth factor: NGF is positively related with ...
Cached Biology News:Boston University biomedical engineers find chink in bacteria's armor 2Boston University biomedical engineers find chink in bacteria's armor 3Minimally invasive heart surgery research wins NIH award 2Targeting nerve growth factor may cure liver cancer 2
... weight determinations for petroleum-based applications. Multiple solvents can be used, such as water, benzene, formamide, ... ... ... ...
Fast, sensitive quantitation of total MEK 1/2 concentration....
... For the ultimate in utility and ... to meet the needs of the researcher. ... interior dimensions or as sheet material that ... enclosures. These isolators are autoclavable and non-cytotoxic ...
... Automatic High Sensitivity Laboratory Osmometer for 50 L samples. Operating head automatically rises at the end of ... ... ... ...
Biology Products: